



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/766,773	01/27/2004	Gregory J. LaRosa	1855.1052-028	3246

26161 7590 03/13/2006

FISH & RICHARDSON PC  
P.O. BOX 1022  
MINNEAPOLIS, MN 55440-1022

EXAMINER
----------

BOESEN, AGNIESZKA

ART UNIT	PAPER NUMBER
----------	--------------

1648

DATE MAILED: 03/13/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/766,773	LARO'SA ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Agnieszka Boesen	1648	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 27 January 2004.
- 2a) ☐ This action is **FINAL**.                      2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 1-38 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☐ Claim(s) \_\_\_\_\_ is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☒ Claim(s) 1-38 are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- |   |   |
|---|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)                        | 4) <input type="checkbox"/> Interview Summary (PTO-413)                     |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)    | Paper No(s)/Mail Date. _____  |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| Paper No(s)/Mail Date _____   | 6) <input type="checkbox"/> Other: _____                                    |

## **DETAILED ACTION**

### ***Election/Restrictions***

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claims 1-4, 9, 10, 13-15, and 22 (in part), drawn to an isolated nucleic acid, expression vector, and a fused gene encoding a humanized immunoglobulin light chain, classified in class 536, subclass 23.53.
  - II. Claims 5-8, 11, 12, 16-18, 22 (in part), drawn to an isolated nucleic acid, expression vector, and a fused gene encoding a humanized immunoglobulin heavy chain, classified in class 536, subclass 23.53.
  - III. Claim 19, drawn to a host cell, an isolated nucleic acid, expression vector, and a fused gene encoding a humanized immunoglobulin heavy and light chain, classified in class 536, subclass 23.53.
  - IV. Claims 20 and 21, drawn to a method of preparing a humanized immunoglobulin, whereby human immunoglobulin chains are expressed and a humanized immunoglobulin is produced, classified in class 435, subclass 69.6.

- V. Claims 23-26, drawn to a method of inhibiting the interaction of a first cell expressing CCR2 and a second cell expressing a ligand of CCR2, classified in class 435, subclass 334.
- VI. Claims 27-30, drawn to a method of treating HIV in a patient, and inhibiting HIV infection in a patient, classified in class 435, subclass 334.
- VII. Claims 31-32, drawn to a method of inhibiting a function associated with binding of a chemokine to mammalian CCR2 or a functional portion of CCR2, classified in class 435, subclass 334.
- VIII. Claims 33-35, drawn to a method of inhibiting leukocyte trafficking in a patient, classified in class 435, subclass 334.
- IX. Claims 36-37, drawn to a method of treating a CCR2- mediated disorder in a patient, classified in class 435, subclass 334.

If Group IX is elected, the Applicant is further required to elect **one** medical disorder in a patient from the following: multiple sclerosis, rheumatoid arthritis, atherogenesis, and atherosclerosis.

Art Unit: 1648

- X. Claim 38, drawn to a method of inhibiting restenosis in patient, classified in class 435, subclass 334.

If Group X is elected, the Applicant is further required to elect **one** medical disorder in a patient.

3. The inventions are distinct, each from the other because of the following reasons:

Inventions I and III are related as combination and subcombination. Inventions in this relationship are distinct if it can be shown that (1) the combination as claimed does not require the particulars of the subcombination as claimed for patentability, and (2) that the subcombination has utility by itself or in other combinations (MPEP § 806.05(c)). In the instant case, the combination as claimed does not require the particulars of the subcombination as claimed because the subcombination specifies the use of SEQ ID NO: 9. The subcombination has separate utility such as in a method to induce an immune response.

Inventions II and III are related as combination and subcombination. Inventions in this relationship are distinct if it can be shown that (1) the combination as claimed does not require the particulars of the subcombination as claimed for patentability, and (2) that the subcombination has utility by itself or in other combinations (MPEP § 806.05(c)). In the instant case, the combination as claimed does not require the particulars of the subcombination as claimed because the subcombination specifies the

Art Unit: 1648

use of SEQ ID NO: 10. The subcombination has separate utility such as in a method to induce an immune response.

Inventions I and II are related as subcombinations disclosed as usable together in a single combination. The subcombinations are distinct if they do not overlap in scope and are not obvious variants, and if it is shown that at least one subcombination is separately usable. See MPEP § 806.05(d).

In the instant case, the nucleic acid of Group I and the nucleic acid of Group II encode different products. The nucleic acid of Group I encodes a protein from the light chain of an antibody, while the nucleic acid of Group II encodes a protein from the heavy chain of the same antibody. The encoded proteins are not obvious over each other because their amino acid sequences are different. The subcombinations of Groups I and II have separate utilities. The nucleic acid of Group I can be used in a method of epitope mapping. The nucleic acid of Group II can be used in a method of inducing an immune response.

The nucleotides of Group (I, II, III) and the methods of Groups (IV, V, VI, VII, VIII, IX, and X) are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product. See MPEP § 806.05(h). In the instant case, the product as claimed can be used in a materially different process of using that product. The nucleotides of Groups (I, II, III)

Art Unit: 1648

can be used for other purposes than to build a construct, which will serve as building blocks in a method of preparing a humanized immunoglobulin of Group IV. For example the nucleotides can be used as a probe for detection of nucleic acids in the sample, and the peptides can be used to generate specific immune responses in a patient. The nucleotides of Groups (I, II, III) can be used for other purposes than using them in a method of inhibiting the interaction of a first cell expressing CCR2 and a second cell expressing a ligand of CCR2 of Group V, a method of treating HIV in a patient of Group VI, a method of inhibiting a function associated with binding of a chemokine to mammalian CCR2 of Group VII, a method of inhibiting leukocyte trafficking in a patient of Group VIII, a method of treating a CCR2- mediated disorder in a patient of Group IX, a method of inhibiting restenosis in patient of Group X. A search for nucleic acid of Groups (I, II, III) is not co-extensive with a search for method of preparing a humanized immunoglobulin of Group IV, or any other methods in Groups V-X. Searching more than one invention and searching all nucleic acid sequences together would present an undue burden for the examiner. Therefore restriction for examination purposes is proper.

Inventions IV, V, VI, VII, VIII, IX, and X are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different designs, modes of operation, and effects (MPEP § 802.01 and § 806.06). ). In the instant case the different inventions are drawn to seven different methods, method of preparing a humanized immunoglobulin of Group IV, a method of inhibiting the

Art Unit: 1648

interaction of a first cell expressing CCR2 and a second cell expressing a ligand of CCR2 of Group V, a method of treating HIV in a patient of Group VI, a method of inhibiting a function associated with binding of a chemokine to mammalian CCR2 of Group VII, a method of inhibiting leukocyte trafficking in a patient of Group VIII, a method of treating a CCR2- mediated disorder in a patient of Group IX, and a method of inhibiting restenosis in a patient of Group X. These methods have different method steps and use different reagents. A search for a method one method is not co-extensive with a search for any other method. In addition even though in some cases the classification is shared, the different search would be required based upon the different method steps and different diseases aimed to be treated with different methods. For example, the literature search, required for Group VI, regarding a method of treating HIV in a patient would not necessarily reveal the literature regarding the a method of inhibiting restenosis in a patient of Group X. It is an undue burden for the examiner to search more than one invention.

Because the inventions are distinct for the reasons given above and the literature and sequence search required for one group is not co-extensive with any other group, and therefore presents a serious burden of search, restriction for examination as indicated is proper. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).



***Notice of Possible Rejoinder***

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. **Process claims that depend from or otherwise include all the limitations of the patentable product** will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai*, *In re Brouwer* and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised

Art Unit: 1648

that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. **Failure to do so may result in a loss of the right to rejoinder.** Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

### ***Conclusion***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Agnieszka Boesen whose telephone number is 571-272-8035. The examiner can normally be reached on M – F (9:00AM - 6:00PM). If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel can be reached on 571-272-0902. The fax phone number for the organization where this application or proceeding is assigned is 571-872-9306.

Art Unit: 1648

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

AB

Agnieszka Boesen  
March 6, 2006

Stacy B. Chen 3/6/06  
Stacy B. Chen  
Patent Examiner